Insmed Incorporated INSM shares are trading higher by $13.80, or 112 percent, at $26.09 in Tuesday's session.
The catalyst for the rally is the announcement of positive top-line results from its Phase 3 Convert study of ALIS in adult patients with treatment-refractory nontuberculous Mycobacterial (NTM) lung disease.
Its much higher opening print of $29.50 is only two cents from the high for the day ($29.52), which exceeds its former all-time high from March 2006 at $27.90.
Since reaching that elevated level, profit-takers have come into Insmed and it has drifted lower. As of 11:15 a.m. EST, the stock has fallen to $25.38 and is trying to remain in the $26.00 handle.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.